Please login to the form below
CRISPR
This page shows the latest CRISPR news and features for those working in and with pharma, biotech and healthcare.
Microfoundations matter
As humans, we are a great example. With our big brains, speech and cultures, we can invent CRISPR and send satellites out of the solar system.
Latest news
-
New T-cell study demonstrates ‘powerful’ potential for tailored cancer medicine
short palindromic repeats (CRISPR) technology, which is used as a means of gene editing and enables scientists to manipulate DNA. ... Particularly critical to this effort was the newly developed ability to use CRISPR to replace immune receptors in
-
ICR study raises possibility of predicting drug resistance in advance
The study, published in the journal Cancer Research, involved the use of the gene editing technology CRISPR to break or switch off each of 25, 000 genes in cancer cells treated
-
Genentech and ArsenalBio join to identify successful T-cell oncology therapies
ArsenalBio’s engineering platform spans a range of cutting-edge technology, including high-throughput CRISPR-based gene editing, synthetic biology and computational biology, to create new synthetic biological programmes aimed at
-
Locus Biosciences announces first patient treated in urinary tract infection trial
The ELIMINATE trial of LBP-EC01 – a CRISPR-enhanced bacteriophage (crPhage) precision medicine – in combination with a commonly used antibiotic will enrol approximately 800 female patients between 18-65 years of ... Paul Garofolo, co-founder and
-
Novartis and Precision BioSciences announce in vivo gene editing collaboration
Widely used ex vivo therapeutic gene-editing techniques such as CRISPR/Cas9 require cells to be removed from the body, edited and reinserted, in a lengthy, expensive and potentially hazardous process.
More from news
Approximately 16 fully matching, plus 37 partially matching documents found.
Latest Intelligence
-
A creative awakening – how pharma is bringing innovation to the patient journey
We can actually make it easier for patients to get the best from the amazing innovation, such as gene therapy and CRISPR, that is coming through.”.
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
With the introduction of new data analytics capabilities and broader adoption in the pharmaceutical industry, research platforms that heavily depend on data (eg, RNAi and CRISPR therapies) will likely increase their
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Horizon Delivery is also an industry leader in CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screenings, meaning they can identify key genes or genetic sequences that draw out specific functions of
-
Switzerland: a life sciences hub
cells engineered to display chimeric antigen receptors) and genome editing (ie, CRISPR/Cas, TALEN, ZNF).
-
25 Women Leaders in UK Healthcare (part 2)
Pioneers in the field include some notable women – such as CRISPR’s co-developers Jennifer Doudna and Emmanuelle Charpentier – although women remain in the minority in both the R&D and
More from intelligence
Approximately 2 fully matching, plus 18 partially matching documents found.
Latest appointments
-
New faces at Merus, Rubius Therapeutics and Titan Pharmaceuticals
Lundberg most recently served as chief scientific officer of CRISPR Therapeutics, where he lead the development of the company’s first clinical trial application. ... Prior to CRISPR, he worked as head of translational medicine at Alexion
-
Former GSK CEO joins Synthego’s advisory board
Their recent rapid advances of the CRISPR field highlight their ability to execute on deep technology with a multidisciplinary, informatics-first approach.
-
Marc Becker joins CRISPR Therapeutics
He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform. ... Becker said: “I am excited to join the CRISPR Therapeutics
-
CRISPR Therapeutics appoints Dr Tony Coles
Swiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors. ... Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Dr Coles is a venerated leader in the biotech industry with a strong track
More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
The fast-paced future of cell and gene therapies
Patient and market access insights on leveraging CRISPR technology for hematologic diseases.
-
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. ... In October 2022, the companies announced their plan to file exagamglogene
-
Disrupting Cell Engineering with Non-Viral Modalities
Jessica Schwaber, Scientific Director, Cell &Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell &gene therapy commercial needs, current barriers to realizing the full potential of cell &gene
-
Creative Animodel
Creative Animodel is an experienced bioscience CRO，which would like to help you accelerate the process through preclinical services including transgenic animals, animal models of disease, CRISPR genome editing technology and
-
Fishawack Health
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access.
More from PMHub
Approximately 3 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Meeting healthcare’s rising challenges
- Why female mentorship is so powerful in pharma
- EU outlines measures to mitigate antibiotic shortage across Europe
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
